Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants
The purpose of this global, multicenter, open-label, Phase 4 clinical extension study is to evaluate the long-term safety and efficacy of revakinagene taroretcel-lwey (Encelto™; hereinafter referred to as NT-501), in participants with macular telangiectasia type 2 (MacTel) who previously received the intraocular implant in a Phase 1, Phase 2, or Phase 3 clinical study and have retained at least 1 NT-501 at study entry. In addition, this study will evaluate the safety and efficacy of NT501 in participants who previously underwent the sham procedure in a Phase 3 MacTel clinical study and elect to have NT-501 implanted intraocularly in this Phase 4 study.
Study details:
This extension study consists of 3 arms:. * Arm 1 (Phase 3 Treated Participants' Long-term Follow-up): Arm 1 is to assess the long-term safety and efficacy of NT-501 in participants who received NT-501 in a previous MacTel Phase 3 clinical study (NTMT-03-A or NTMT-03-B) and have retained at least 1 NT-501at study entry. * Arm 2 (Phase 1 and Phase 2 Long-term Follow-up): Similar to Arm 1, Arm 2 is to assess the long-term safety of NT-501 in participants who received NT-501 in a previous MacTel Phase 1 or Phase 2 clinical study (NTMT-01, NTMT-02, or NTMT-01/02E) and have retained at least 1 NT-501 at study entry.
* Arm 3 (Phase 3 Sham to Implant Crossover): Arm 3 will evaluate the safety and efficacy of NT-501 in participants who previously underwent the sham procedure in a Phase 3 MacTel clinical study (NTMT-03-A or NTMT-03-B) and elect to have NT-501 implanted intraocularly in this extension study. Arms 1 and 2 are noninterventional and observational studies. For participants who previously received a single NT-501 implant, the implanted eye is designated the study eye.
For participants who received an NT-501 in both eyes (ie, the first implant received in NTMT-01, NTMT-02, NTMT-01/02E, NTMT-03A, or NTMT-03B, and the second implant received in NTMT-02B), both eyes will be designated as study eyes. Only participants in Arm 3 will receive active intervention during this Phase 4 study. A participant can receive NT-501 in either eye that meets eligibility criteria according to investigator assessment, and in accordance with participant choice.
However, if only 1 eye is eligible for implantation based on all inclusion/exclusion criteria, then that eye will be selected for NT-501 implantation. The eye selected for NT-501 implantation will be designated as the study eye. Regardless of study eye designation, both eyes of each participant in all 3 study arms will be evaluated during the study.
Eligibility criteria
Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.
Inclusion criteria
- Male or female adult participants who previously completed an NT-501 MacTel clinical study and: Arm 1: received NT-501 intraocular implant in either Phase 3 study (NTMT-03-A or NTMT-03-B), Arm 2: received NT-501 intraocular implant in the Phase 1 study (NTMT-01), Phase 2 study (NTMT-02), or in the substudy of the Phase 1 and Phase 2 extension study (NTMT-01/02E), Arm 3: underwent the sham procedure in either Phase 3 study (NTMT-03-A or NTMT-03-B)
- Participants must have steady fixation in the foveal or parafoveal area and sufficiently clear media for good quality retinal imaging.
- Participant or their legally authorized representative must be able to provide written informed consent to participate in the study, in accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) guidelines, and local regulations, before initiating any clinical study related procedures.
- Arm 3: female participants of childbearing potential must agree to use highly effective contraception.
Exclusion criteria
- Participant is medically unable to comply with clinical study procedures or visits.
- Participant has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations, and outcome assessments.
- Participant has significant corneal or media opacities in the study eye to be implanted.
- Participant has evidence of pathologic myopia in the study eye to be implanted.
- Participant has any of the following lens opacities in the study eye to be implanted: cortical opacity > standard 3, posterior subcapsular opacity > standard 2, or a nuclear opacity > standard 3 as measured on the Age- Related Eye Disease Study (AREDS) clinical lens grading system.
- Participant has undergone lens removal in the study eye to be implanted in the previous 3 months or YAG laser within 4 weeks of the screening/baseline visit.
- Participant has evidence of ocular disease in the study eye to be implanted other than MacTel that, in the judgment of the examining physician, may confound the diagnosis, procedures, or outcome of the study (eg. glaucoma, severe nonproliferative or proliferative diabetic retinopathy, uveitis).
- Received intravitreal steroid therapy in the study eye to be implanted within the last year.
- Received intravitreal anti-vascular endothelial growth factor therapy in the study eye to be implanted within the last 6 months.
- Evidence of active exudative intraretinal neovascularization or subretinal neovascularization in the study eye to be implanted, as evidenced by hemorrhage, hard exudate, subretinal fluid, or intraretinal fluid.
- Evidence of central serous chorioretinopathy in the study eye to be implanted.
- Participant underwent vitrectomy, penetrating keratoplasty, trabeculectomy, or trabeculoplasty in the study eye to be implanted.
- A history of ocular herpes virus in the study eye to be implanted.
- Participant is on chemotherapy.
- Participant is pregnant or breastfeeding.
- Participation in any other clinical study of an intervention (drug or device) within 6 months prior to the screening/baseline visit.
- A history of malignancy that would compromise survival during the clinical study.
Eligibility
Age eligible for study : NA
Healthy volunteers accepted : No
Gender eligible for study: ALL
Things to know
Study dates
Study start:
Primary completion:
Study completion finish:
Study type
TREATMENT
Phase
- PHASE4
Study ID
NCT06971939
Intervention or treatment
COMBINATION_PRODUCT: NT-501/revakinagene taroretcel-lwey
Conditions
- Macular Telangiectasia Type 2 (MacTel)
You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.
Research sites nearby
Closest Location:
Lion's Eye Institute
Select from list below to view details:
Lion's Eye Institute
Perth, Australia
Cerulea
East Melbourne, Australia
Sydney Eye Hospital
Sydney, Australia
Loading map...
Who is running the clinical trial?
Neurotech Pharmaceuticals
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
| Participant Group/Arm | Intervention/Treatment |
|---|---|
OTHER: Arm 1 (Phase 3 Long-term Follow-up)
| Combination Product: NT-501/revakinagene taroretcel-lwey |
OTHER: Arm 2 (Phase 1 and Phase 2 Long-term Follow-up)
| Combination Product: NT-501/revakinagene taroretcel-lwey |
EXPERIMENTAL: Arm 3 (Phase 3 Sham to Implant Crossover)
| Combination Product: NT-501/revakinagene taroretcel-lwey |
What is the study measuring?
Primary Outcome
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of ocular and nonocular adverse events (AEs) and serious adverse events (SAEs) | Incidence of ocular and nonocular adverse events (AEs) and serious adverse events (SAEs) | Baseline and annually for up to 5 yrs for Arms 1 and 2 and baseline, perioperative, and annually for up to 5 yrs for Arm 3 participants |
| Percentage of participants with a loss of 15 letters or more in best corrected visual acuity (BCVA) compared to presurgery baseline BCVA | Percentage of participants with a loss of 15 letters or more in best corrected visual acuity (BCVA) compared to presurgery baseline BCVA using the Early Treatment Diabetic Retinopathy Study (ETDRS) distance chart | Baseline and annually for up to 5 yrs for Arms 1 and 2 and baseline, perioperative, and annually for up to 5 yrs for Arm 3 participants |
Secondary Outcome
| Measure | Description | Time Frame |
|---|---|---|
| Change from presurgery baseline in ellipsoid zone (EZ) area loss | Change from presurgery baseline in ellipsoid zone (EZ) area loss as measured by en face spectral domain optical coherence tomography (SD-OCT) for both eyes | Baseline and annually for up to 5 yrs for Arms 1 and 2 and baseline, perioperative, and annually for up to 5 yrs for Arm 3 participants |
| Change from presurgery baseline in BCVA | Change from presurgery baseline in BCVA using the ETDRS distance chart for both eyes | Baseline and annually for up to 5 yrs for Arms 1 and 2 and baseline, perioperative, and annually for up to 5 yrs for Arm 3 participants |
| Change from presurgery baseline in aggregate retinal sensitivity | Change from presurgery baseline in aggregate retinal sensitivity as measured by microperimetry within the EZ line break area for both eyes | Baseline and annually for up to 5 yrs for Arms 1 and 2 and baseline, perioperative, and annually for up to 5 yrs for Arm 3 participants |
| Change from presurgery baseline in monocular reading speed | Change from presurgery baseline in monocular reading speed for both eyes | Baseline and annually for up to 5 yrs for Arms 1 and 2 and baseline, perioperative, and annually for up to 5 yrs for Arm 3 participants |
| Change from presurgery baseline in the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) | Change from presurgery baseline in NEI-VFQ-25 near activities subscale score. All items are scored so that a high score represents better functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. | Baseline and annually for up to 5 yrs for Arms 1 and 2 and baseline, perioperative, and annually for up to 5 yrs for Arm 3 participants |
References
Clinical Trials Gov: Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure ParticipantsOther trials to consider
Loading suggested trials...